Bristol Myers is cleaning up the post-Celgene merger pipeline, and they’re sweeping out an experimental checkpoint in the process
Back during the lead up to the $74 billion buyout of Celgene, the big biotech’s leadership did a little housecleaning with a major …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
